

MARKET REPORT



Colitis - Pipeline Review, H1 2017

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Colitis - Pipeline Review, H1 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Colitis - Pipeline Review, H1 2017

Colitis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2017, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

Publisher : Global Markets Direct

Reference : GMDHC8965IDB

Number of Pages : 94

Report Format : PDF

Publisher Information :

Global Markets Direct
The home of leading edge research and analysis

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Colitis - Pipeline Review, H1 2017

- Table of ContentsList of TablesList of FiguresIntroductionGlobal Markets Direct Report CoverageColitis - OverviewColitis - Therapeutics DevelopmentPipeline OverviewPipeline by CompaniesPipeline by Universities/InstitutesProducts under Development by CompaniesProducts under Development by Universities/InstitutesColitis - Therapeutics AssessmentAssessment by TargetAssessment by Mechanism of ActionAssessment by Route of AdministrationAssessment by Molecule TypeColitis - Companies Involved in Therapeutics DevelopmentAkebia Therapeutics IncBristol-Myers Squibb CompanyConcenter BioPharma Silkim LtdCosmo Pharmaceuticals NVCSA Biotechnologies LLCDr. Falk Pharma GmbHEA Pharma Co LtdGenfit SAImmuron LtdInnate Pharma SAOgeda SAPeptinov SASPfizer IncRDD Pharma LtdSaniona ABSigmoid Pharma LtdSoligenix IncSynovo GmbHColitis - Drug ProfilesAcTMP-1 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAKB-6899 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAN-346 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAntibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAntibody for Colitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAntisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAPY-0201 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBC-1215 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBMS-986104 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressbudesonide - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCSA-13 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCSY-0073 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressdimethylxalylglycine - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressDrugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressdusquetide - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresselafibranor - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressESN-601 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressIMM-124E - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressIPH-33 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNK-007 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPeptide to Inhibit NFkB for Colitis and Enteritis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPF-06425090 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPPV-06 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRDD-2007 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRecombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressrifamycin CR - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRP-182 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecule for Colitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecule for Crohn's Disease and Colitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSynthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressTPC-1022 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressVaccine to Target IL12 and IL23 for Colitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressVaccine to Target IL23 for Colitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressColitis - Dormant ProjectsColitis - Discontinued ProductsColitis - Product Development MilestonesFeatured News & Press ReleasesJun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMXAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer

How to Buy...

Colitis - Pipeline Review, H1 2017

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/47380>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$1700** | Single User Price
- \$3400** | Site License Price
- \$5100** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.